<?xml version="1.0" encoding="UTF-8"?>
<p id="p0130">HDV RNA was tested in 5,073 anti-HDV positive people. The pooled proportion with HDV RNA detection was 58.5% (95% CI 52.4–64.5) (
 <xref rid="appsec1" ref-type="sec">supplementary appendix 21</xref>). Overall, HDV RNA prevalence correlated with anti-HDV prevalence, with a coefficient of 0.03 (95% CI 0.02–0.06; 
 <italic>p</italic> &lt;0.0001) indicating a 3% increase in HDV RNA detection per each 10% increase in anti-HDV prevalence. HDV RNA detection was lower in general populations relative to hepatology clinic populations (coefficient −0.20; 95% CI −0.33 to −0.07; 
 <italic>p</italic> = 0.003). There was also lower HDV RNA detection in the African region compared to other WHO regions (41.3% 
 <italic>vs.</italic> 64.9%; coefficient −0.13; 95% CI −0.26 to −0.002; 
 <italic>p</italic> = 0.05). Subject to the limitations of the available data, a preliminary estimate of 7.1 million people (95% CI 5.0–11.1) had viraemic infection (HDV RNA positive), representing a general population prevalence of viraemia of 0.09% (95% CI 0.07–0.15).
</p>
